RUNX1T1 and acute myeloid leukemia: Further evaluation both ex vivo in patient-derived AML cells and in vivo in immunodeficient mice transplanted with RUNX1/ETO-expressing AML cells demonstrated a high sensitivity of this AML subtype to palbociclib inhibition.